ICOS ligand costimulation is required for T-cell encephalitogenicity
Copyright 2001 Academic Press.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 100(2001), 3 vom: 01. Sept., Seite 277-88 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , , |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2001
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Antigens, Differentiation, T-Lymphocyte CD28 Antigens Cytokines Icos protein, mouse Inducible T-Cell Co-Stimulator Protein Ligands Proto-Oncogene Proteins c-bcl-2 |
| Zusammenfassung: | Copyright 2001 Academic Press. The interaction of ICOS with its ligand on APC provides a costimulatory signal to previously activated T-cells. In these studies, we blocked the ICOS:ICOS ligand interaction with ICOS-Ig during the in vitro activation of MBP-reactive transgenic CD4(+) T-cells. The presence of ICOS-Ig in these cultures inhibited the ability of the transgenic T-cells to transfer EAE, although they entered the brains of the recipient mice. ICOS-Ig increased apoptosis in the transgenic T-cells, especially in the memory population. This enhanced apoptosis was accompanied by an increase in the BAX/BCL-2 mRNA ratio. ICOS-Ig did not prevent IL2 production, demonstrating that IL-2 production is ICOS ligand independent. IFN-gamma and IL-10 production by the transgenic T-cells, however, was suppressed. Finally, ICOS-Ig injection into mice after the first signs of EAE ameliorated clinical disease. Therefore, ICOSL provides a signal distinct from CD28 costimulation that is required for the activation and viability of encephalitogenic T-cells |
|---|---|
| Beschreibung: | Date Completed 20.09.2001 Date Revised 16.11.2017 published: Print CommentIn: Clin Immunol. 2001 Sep;100(3):261-2. - PMID 11513538 Citation Status MEDLINE |
| ISSN: | 1521-7035 |